These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Prediction of Antimicrobial Potential of a Chemically Modified Peptide From Its Tertiary Structure. Agrawal P; Raghava GPS Front Microbiol; 2018; 9():2551. PubMed ID: 30416494 [TBL] [Abstract][Full Text] [Related]
12. [Chemical Approaches for RNAi Drug Development]. Saito-Tarashima N Yakugaku Zasshi; 2020; 140(10):1259-1268. PubMed ID: 32999205 [TBL] [Abstract][Full Text] [Related]
13. Insights from crystallographic studies into the structural and pairing properties of nucleic acid analogs and chemically modified DNA and RNA oligonucleotides. Egli M; Pallan PS Annu Rev Biophys Biomol Struct; 2007; 36():281-305. PubMed ID: 17288535 [TBL] [Abstract][Full Text] [Related]
14. Assembling the RNA therapeutics toolbox. Teng M; Xia ZJ; Lo N; Daud K; He HH Med Rev (2021); 2024 Apr; 4(2):110-128. PubMed ID: 38680684 [TBL] [Abstract][Full Text] [Related]
15. siRNAmod: A database of experimentally validated chemically modified siRNAs. Dar SA; Thakur A; Qureshi A; Kumar M Sci Rep; 2016 Jan; 6():20031. PubMed ID: 26818131 [TBL] [Abstract][Full Text] [Related]
16. Advances in Nanoparticles for Effective Delivery of RNA Therapeutics. Byun MJ; Lim J; Kim SN; Park DH; Kim TH; Park W; Park CG Biochip J; 2022; 16(2):128-145. PubMed ID: 35261724 [TBL] [Abstract][Full Text] [Related]
17. How the initial discovery of modified RNA enabled evasion of innate immune responses and facilitated the development of RNA therapeutics. Sioud M Scand J Immunol; 2023 Jul; 98(1):e13282. PubMed ID: 37132451 [TBL] [Abstract][Full Text] [Related]